199 related articles for article (PubMed ID: 23494963)
1. Pharmacokinetic and pharmacodynamic profile of rosuvastatin in patients with end-stage renal disease on chronic haemodialysis.
Birmingham BK; Swan SK; Puchalski T; Mitchell P; Azumaya C; Zalikowski J; Wang Y
Clin Drug Investig; 2013 Apr; 33(4):233-41. PubMed ID: 23494963
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of rosuvastatin in healthy Chinese volunteers living in China: a randomized, open-label, ascending single- and multiple-dose study.
Li XN; Xu HR; Chen WL; Chu NN; Zhu JR
Clin Ther; 2010 Mar; 32(3):575-87. PubMed ID: 20399994
[TBL] [Abstract][Full Text] [Related]
3. Pharmacodynamic interaction between ezetimibe and rosuvastatin.
Kosoglou T; Statkevich P; Yang B; Suresh R; Zhu Y; Boutros T; Maxwell SE; Tiessen R; Cutler DL
Curr Med Res Opin; 2004 Aug; 20(8):1185-95. PubMed ID: 15324521
[TBL] [Abstract][Full Text] [Related]
4. Pharmacodynamic effects and pharmacokinetics of a new HMG-CoA reductase inhibitor, rosuvastatin, after morning or evening administration in healthy volunteers.
Martin PD; Mitchell PD; Schneck DW
Br J Clin Pharmacol; 2002 Nov; 54(5):472-7. PubMed ID: 12445025
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of rosuvastatin in patients with end-stage kidney disease undergoing peritoneal dialysis.
Bologa R; Levine D; Parker T; Gordon B; Lanto A; Cheigh J; Stenzel K; Rubin A
Clin Nephrol; 2009 Dec; 72(6):437-41. PubMed ID: 19954720
[TBL] [Abstract][Full Text] [Related]
6. Population pharmacokinetics of rosuvastatin: implications of renal impairment, race, and dyslipidaemia.
Tzeng TB; Schneck DW; Birmingham BK; Mitchell PD; Zhang H; Martin PD; Kung LP
Curr Med Res Opin; 2008 Sep; 24(9):2575-85. PubMed ID: 18674408
[TBL] [Abstract][Full Text] [Related]
7. Rosuvastatin: a review of its use in the management of dyslipidemia.
Scott LJ; Curran MP; Figgitt DP
Am J Cardiovasc Drugs; 2004; 4(2):117-38. PubMed ID: 15049723
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic properties of rosuvastatin after single-dose, oral administration in Chinese volunteers: a randomized, open-label, three-way crossover study.
Li Y; Jiang X; Lan K; Zhang R; Li X; Jiang Q
Clin Ther; 2007 Oct; 29(10):2194-203. PubMed ID: 18042475
[TBL] [Abstract][Full Text] [Related]
9. Absolute oral bioavailability of rosuvastatin in healthy white adult male volunteers.
Martin PD; Warwick MJ; Dane AL; Brindley C; Short T
Clin Ther; 2003 Oct; 25(10):2553-63. PubMed ID: 14667956
[TBL] [Abstract][Full Text] [Related]
10. Steady-state pharmacokinetic interactions of darunavir/ritonavir with lipid-lowering agent rosuvastatin.
Samineni D; Desai PB; Sallans L; Fichtenbaum CJ
J Clin Pharmacol; 2012 Jun; 52(6):922-31. PubMed ID: 21712498
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of rosuvastatin in treatment of dyslipidemia.
McKenney JM
Am J Health Syst Pharm; 2005 May; 62(10):1033-47. PubMed ID: 15901588
[TBL] [Abstract][Full Text] [Related]
12. Treatment and prevention of dyslipidemia with rosuvastatin (Crestor).
Leonard KA
Nurse Pract; 2004 May; 29(5):11-5. PubMed ID: 15167530
[No Abstract] [Full Text] [Related]
13. Pharmacokinetics and pharmacodynamics of rosuvastatin in subjects with hepatic impairment.
Simonson SG; Martin PD; Mitchell P; Schneck DW; Lasseter KC; Warwick MJ
Eur J Clin Pharmacol; 2003 Feb; 58(10):669-75. PubMed ID: 12610743
[TBL] [Abstract][Full Text] [Related]
14. Eltrombopag increases plasma rosuvastatin exposure in healthy volunteers.
Allred AJ; Bowen CJ; Park JW; Peng B; Williams DD; Wire MB; Lee E
Br J Clin Pharmacol; 2011 Aug; 72(2):321-9. PubMed ID: 21434975
[TBL] [Abstract][Full Text] [Related]
15. Efficacy analysis of the lipid-lowering and renoprotective effects of rosuvastatin in patients with chronic kidney disease.
Abe M; Maruyama N; Yoshida Y; Ito M; Okada K; Soma M
Endocr J; 2011; 58(8):663-74. PubMed ID: 21670545
[TBL] [Abstract][Full Text] [Related]
16. A double-blind, randomized, incomplete crossover trial to assess the dose proportionality of rosuvastatin in healthy volunteers.
Martin PD; Warwick MJ; Dane AL; Cantarini MV
Clin Ther; 2003 Aug; 25(8):2215-24. PubMed ID: 14512129
[TBL] [Abstract][Full Text] [Related]
17. An open-label, randomized, three-way crossover trial of the effects of coadministration of rosuvastatin and fenofibrate on the pharmacokinetic properties of rosuvastatin and fenofibric acid in healthy male volunteers.
Martin PD; Dane AL; Schneck DW; Warwick MJ
Clin Ther; 2003 Feb; 25(2):459-71. PubMed ID: 12749507
[TBL] [Abstract][Full Text] [Related]
18. Effects of lipid-lowering therapy with rosuvastatin on atherosclerotic burden in patients with chronic kidney disease.
Sawara Y; Takei T; Uchida K; Ogawa T; Yoshida T; Tsuchiya K; Nitta K
Intern Med; 2008; 47(17):1505-10. PubMed ID: 18758125
[TBL] [Abstract][Full Text] [Related]
19. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis.
Fellström BC; Jardine AG; Schmieder RE; Holdaas H; Bannister K; Beutler J; Chae DW; Chevaile A; Cobbe SM; Grönhagen-Riska C; De Lima JJ; Lins R; Mayer G; McMahon AW; Parving HH; Remuzzi G; Samuelsson O; Sonkodi S; Sci D; Süleymanlar G; Tsakiris D; Tesar V; Todorov V; Wiecek A; Wüthrich RP; Gottlow M; Johnsson E; Zannad F;
N Engl J Med; 2009 Apr; 360(14):1395-407. PubMed ID: 19332456
[TBL] [Abstract][Full Text] [Related]
20. Rosuvastatin: a high-potency HMG-CoA reductase inhibitor.
Lopez LM
J Am Pharm Assoc (2003); 2005; 45(4):503-13. PubMed ID: 16128507
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
